← All trials
NCT05119712
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2021
- Primary completion
- Oct 15, 2023
- Completion date
- Oct 15, 2024
- First posted
- Nov 15, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Oregon Health and Science UniversityReponsible party - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- The Malassezia FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.